On Jul. 6, 2023, Eisai and Biogen announced that the U.S. Food and Drug Administration (FDA) had approved the…
On Jun. 22, 2023, the U.S. Food and Drug Administration (FDA) approved Sarepta Therapeutics’s Elevidys, the first gene…
On Jun. 2, 2023 AquaBounty Technologies announced that the Company will pause the construction of its farm in…
On May 3, 2023, Vertex announced the Food and Drug Administration (FDA) had approved KALYDECO (ivacaftor) for use…
On Apr. 26, 2023, Vertex announced the Food and Drug Administration (FDA) had approved the expanded use of…
On Apr. 20, 2023, Massachusetts Institute of Technology (MIT) researchers announced that have developed machine-learning algorithms that can…
On Apr. 17, 2023, the U.S. Food and Drug Administration (FDA) approved Gamida Cell’s Omisirge (omidubicel-onlv), a substantially…
On Apr. 4, 2023, National Institutes of Health (NIH) funded research was announced from the University of Rochester…
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
On Mar. 20, 2023, some of the world’s leading makers of flu vaccines said they could make hundreds…
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
On Aug. 22, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Moderna…
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 17, 2022, the U.S. Food and Drug Administration (FDA) authorized emergency use of the Moderna COVID-19…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, The European Commission and the vaccine developer Moderna announced they have reached an agreement…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 31, 2022, Ultima Genomics emerged from stealth business mode with a new high-throughput, low-cost sequencing platform…
On May 25, 2022, the Health and Human Services agency (HHS) announced the formal establishment of the Advanced…
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, scientists at the Centers for Disease Control and Prevention (CDC) announced that they were…